NCT02101775 2026-03-19
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT04439227 2025-10-31
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03284385 2025-10-27
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03253679 2023-10-17
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
National Cancer Institute (NCI)
Phase 2 Completed
NCT01827384 2023-09-29
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
National Cancer Institute (NCI)
Phase 2 Completed